In early June 2008, Third Wave Technologies was acquired by Hologic, Inc., of Bedford, MA. Operting as a wholly owned subsiduray of Hologic, Third Wave Technologies, Inc. engages in the development and marketing of molecular diagnostic products for various DNA and RNA analysis applications. It provides physicians and researchers with molecular solutions for the analysis and treatment of disease. Hologic holds the number one position in nine technology areas serving woman's health, including breast cancer diagnosis and treatment, cervical cancer screening, prenatal testing and osteoporosis detection. Hologic believes that the health issues facing women today deserve and demand the singular dedication of a passionate company.The company offers products based proprietary Invader chemistry, a technology used in women's health, infectious disease, genetics and pharmacogenetics, and oncology segments. Third Wave principally offers inVitro diagnostic devices and analyte specific reagents. The company's analyte specific reagents allow laboratories to create assays to perform hepatitis C virus genotyping, inherited disorders testing, and a host of other mutations associated with genetic predispositions and other diseases. Third Wave also develops various DNA and RNA analysis products for the research and agricultural biotechnology markets. Its customers include clinical laboratories, pharmaceutical and biotechnology companies, academic research centers, and health care providers. Third Wave sells its products through a combination of direct sales personnel who focuses primarily on the clinical market, as well as through collaborative relationships in the United States and Europe.
